Friday, July 31, 2026

K-Bio Targets the U.S. Market: Celltrion and Samsung Bioepis Close in on Originator Drugs

Celltrion and Samsung Bioepis are expanding in the U.S. market, showing strong growth in biosimilars like Zymfentra and Hadlima.

FBI: That Voice Message from a Top Official? It Could Be a Fake

The FBI warns of AI-driven deepfake scams impersonating officials to deceive victims into clicking malicious links. Stay vigilant!

THE GREAT SOUTH KOREAN HYPOCRISY: Money For ‘Peace’ Is More Important Than North Korean Suffering

The National Assembly approved a budget for the Korea Peace Center, reallocating funds from the North Korean Human Rights Center.

Tag: metabolic diseases

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

How Salidroside from Korean Ginseng Can Combat Insulin Resistance and Prevent Diabetes

Research reveals salicin from tianma improves insulin resistance, aiding diabetes prevention and intestinal health restoration.

Metabolic Surgery for Obese Seniors: A Safe Solution for Diabetes and Hypertension?

A study shows metabolic obesity surgery is safe for patients over 55, improving diabetes and other metabolic diseases effectively.

K-Bio shifts focus to clinical data as key trial readouts stack up in second half

Korea's biotech sector shifts focus to clinical data in H2 2023, with key results from leading companies expected to drive investor sentiment.

Celltrion Moves CT-G32 Into Final Preclinical Stage as Global Obesity Trial Preparation Accelerates

Celltrion advances CT-G32, a next-gen obesity treatment, targeting multiple pathways to enhance weight loss while preserving muscle mass.

Frequent Delivery Meals and Abdominal Obesity Emerging as Key Drivers of Early Hypertension Risk

Increased use of delivery apps and late-night eating habits are raising hypertension and metabolic disease risks among young adults.

JW Pharmaceuticals Secures Exclusive Rights for Innovative GLP-1 Drug Vopaglutide in South Korea

JW Pharmaceutical secures exclusive rights for Vopaglutide, a promising treatment for diabetes and obesity, with significant milestone payments.

New Obesity Drug Shows Big Promise — and It’s Not from Eli Lilly or Novo

Metsera leads emerging obesity treatments with promising drug MET-233i, showing significant weight loss in trials, amid rising competition.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.